CALR and cancer: Neoadjuvant chemotherapy promotes TLS formation, adaptive immunity, and maturation in metastatic HCSOC lesions.Intracellular calreticulin (CALR) expression within cancer cells, a marker of endoplasmic reticulum stress and potential cell death, was increased.Suggests clinical trial with chemo + ICI.